Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Pharm ; 646: 123502, 2023 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-37827392

RESUMO

The increasing prevalence of non-healing infected wounds has become a serious concern in the clinical practice, being associated to population aging and to the rising prevalence of several chronic conditions such as diabetes. Herein, the evaluation of the bactericidal and antibiofilm effects of the natural antiseptic terpenes thymol and farnesol standing alone or in combination with the standard care antiseptic chlorhexidine was carried out both in vitro and in vivo. The in vitro combinatorial treatment of chlorhexidine associated with those terpenes against Staphylococcus aureus in its planktonic and sessile forms demonstrated a superior antibacterial activity than that of chlorhexidine alone. Real-time in vivo monitoring of infection progression and antimicrobial treatment outcomes were evaluated using the bioluminescent S. aureus strain Xen36. In vivo studies on infected wound splinting murine models corroborated the superior bactericidal effects of the combinatorial treatments here proposed. Moreover, the encapsulation of thymol in electrospun Eudragit® S100 (i.e., a synthetic anionic copolymer of methacrylic acid and ethyl acrylate)-based wound dressings was also carried out in order to design efficient antimicrobial wound dressings.


Assuntos
Anti-Infecciosos Locais , Anti-Infecciosos , Infecção dos Ferimentos , Humanos , Animais , Camundongos , Clorexidina/farmacologia , Staphylococcus aureus , Timol/farmacologia , Anti-Infecciosos Locais/farmacologia , Antibacterianos , Anti-Infecciosos/farmacologia , Infecção dos Ferimentos/tratamento farmacológico
2.
Int J Pharm X ; 5: 100178, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36970713

RESUMO

The potential gain in efficacy of pulmonary administration over IV administration of some antibiotics such as ciprofloxacin (CIP) may be limited by the short residence time of the drug at the site of infection after nebulization. Complexation of CIP with copper reduced its apparent permeability in vitro through a Calu-3 cell monolayer and greatly increased its pulmonary residence time after aerosolisation in healthy rats. Chronic P. aeruginosa lung infections in cystic fibrosis patients result in airway and alveolar inflammation that may increase the permeability of inhaled antibiotics and alter their fate in the lung after inhalation compared to what was seen in healthy conditions. The objective of this study was to compare the pharmacokinetics and efficacy of CIP-Cu2+ complex-loaded microparticles administered by pulmonary route with a CIP solution administered by IV to model rats with chronic lung infection. After a single pulmonary administration of microparticles loaded with CIP-Cu2+ complex, pulmonary exposure to CIP was increased 2077-fold compared to IV administration of CIP solution. This single lung administration significantly reduced the lung burden of P. aeruginosa expressed as CFU/lung measured 24 h after administration by 10-fold while IV administration of the same dose of CIP was ineffective compared to the untreated control. This better efficacy of inhaled microparticles loaded with CIP-Cu2+ complex compared with CIP solution can be attributed to the higher pulmonary exposure to CIP obtained with inhaled CIP-Cu2+ complex-loaded microparticles than that obtained with IV solution.

3.
Med Mycol ; 59(7): 694-700, 2021 Jul 06.
Artigo em Inglês | MEDLINE | ID: mdl-33369666

RESUMO

Alveolar macrophages (AM) are the first-line lung defense against Mucorales in pulmonary mucormycosis. Since corticosteroid use is a known risk factor for mucormycosis, the aim of this study was to describe the role of corticosteroids on AM capacities to control Lichtheimia corymbifera spore growth using a new ex vivo model. An in vivo mouse model was developed to determine the acetate cortisone dose able to trigger pulmonary invasive infection. Then, in the ex vivo model, male BALB/c mice were pretreated with the corticosteroid regimen triggering invasive infection, before AM collection through bronchoalveolar lavage. AMs from corticosteroid-treated mice and untreated control AMs were then exposed to L. corymbifera spores in vitro (ratio 1:5). AM control of fungal growth, adherence/phagocytosis, and oxidative burst were assessed using optical densities by spectrophotometer, flow cytometry, and 2', 7'-dichlorofluoresceine diacetate fluorescence, respectively. Cortisone acetate at 500 mg/kg, at D-3 and at D0, led to pulmonary invasive infection at D3. Co-incubated spores and AMs from corticosteroid-treated mice had significantly higher absorbance (fungal growth) than co-incubated spores and control AMs, at 24 h (P = .025), 36 h (P = .004), and 48 h (P = .001). Colocalization of spores with AMs from corticosteroid-treated mice was significantly lower than for control AMs (7.6 ± 1.9% vs 22.3 ± 5.8%; P = .003), reflecting spore adherence and phagocytosis inhibition. Finally, oxidative burst was significantly increased when control AMs were incubated with spores (P = 0.029), while corticosteroids hampered oxidative burst from treated AMs (P = 0.321). Corticosteroids enhanced fungal growth of L. corymbifera through AM phagocytosis inhibition and burst oxidative decrease in our ex vivo model. LAY SUMMARY: The aim of this study was to describe the impact of corticosteroids on alveolar macrophage (AM) capacities to control Mucorales growth in a new murine ex vivo model. Corticosteroids enhanced fungal growth of L. corymbifera through AM phagocytosis inhibition and burst oxidative decrease.


Assuntos
Corticosteroides/administração & dosagem , Pulmão/microbiologia , Macrófagos Alveolares/efeitos dos fármacos , Mucorales/efeitos dos fármacos , Fagocitose/efeitos dos fármacos , Esporos Fúngicos/efeitos dos fármacos , Animais , Modelos Animais de Doenças , Humanos , Pulmão/efeitos dos fármacos , Macrófagos Alveolares/microbiologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Mucorales/crescimento & desenvolvimento , Mucormicose/imunologia , Mucormicose/microbiologia
4.
Pharmaceutics ; 12(6)2020 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-32560289

RESUMO

To assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder prepared by spray drying was characterized by a mass median aerodynamic diameter and fine particle fraction of 2.68 ± 0.07 µm and 59.5 ± 5.4%, respectively, when emitted from a Handihaler®. After intratracheal administration, the average pulmonary epithelial lining fluid (ELF): plasma area under the concentration versus time curves (AUC) ratios were 570 and 95 for the COLI solution and powder, respectively. However, the same COLI plasma concentration profiles were obtained with the two formulations. According to our pharmacokinetic model, this difference in ELF COLI concentration could be due to faster systemic absorption of COLI after the powder inhalation than for the solution. In addition, the COLI apparent permeability (Papp) across a Calu-3 epithelium model increased 10-fold when its concentration changed from 100 to 4000 mg/L. Based on this last result, we propose that the difference observed in vivo between the COLI solution and powder could be due to a high local ELF COLI concentration being obtained at the site where the dry particles impact the lung. This high local COLI concentration can lead to a local increase in COLI Papp, which is associated with a high concentration gradient and could produce a high local transfer of COLI across the epithelium and a consequent increase in the overall absorption rate of COLI.

5.
Artigo em Inglês | MEDLINE | ID: mdl-30962337

RESUMO

The aim of this study was to investigate the pharmacokinetics of oseltamivir phosphate, a prodrug, and its active moiety in plasma and lung after its nebulization and intravenous administration in rats. Only 2% of prodrug was converted into active moiety presystematically, attesting to a low advantage of oseltamivir phosphate nebulization, suggesting that oseltamivir phosphate nebulization is not a good option to obtain a high exposure of the active moiety at the infection site within lung.


Assuntos
Oseltamivir/análogos & derivados , Oseltamivir/farmacocinética , Pró-Fármacos/farmacocinética , Administração Intravenosa , Animais , Masculino , Oseltamivir/administração & dosagem , Oseltamivir/sangue , Oseltamivir/farmacologia , Fosfatos , Pró-Fármacos/administração & dosagem , Ratos , Ratos Sprague-Dawley
6.
Artigo em Inglês | MEDLINE | ID: mdl-30012776

RESUMO

The purpose of this study was to investigate aztreonam (ATM) and avibactam (AVI) distribution in intraperitoneal fluid and muscle interstitial fluid by microdialysis in rats, with or without peritonitis, and to compare the unbound concentrations in tissue with the unbound concentrations in blood. Microdialysis probes were inserted into the jugular veins, hind leg muscles, and peritoneal cavities of control rats (n = 5) and rats with intra-abdominal sepsis (n = 9) induced by cecal ligation and punctures. ATM and AVI probe recoveries in each medium were determined for both molecules in each rat by retrodialysis by drug. ATM-AVI combination was administered as an intravenous bolus at a dose of 100-25 mg · kg-1 Microdialysis samples were collected over 120 min, and ATM-AVI concentrations were determined by liquid chromatography-tandem mass spectrometry. Noncompartmental pharmacokinetic analysis was conducted and nonparametric tests were used for statistical comparisons between groups (infected versus control) and medium. ATM and AVI distribution in intraperitoneal fluid and muscle was rapid and complete both in control rats and in rats with peritonitis, and the concentration profiles in blood, intraperitoneal fluid, and muscle were virtually superimposed, in control and infected animals, both for ATM and AVI. No statistically significant difference was observed between unbound tissue extracellular fluid and systemic areas under the curve for both molecules in control and infected animals. In the present study, intraperitoneal infection induced by cecal ligation and puncture had no apparent effect on ATM and AVI pharmacokinetics in rats.


Assuntos
Compostos Azabicíclicos/farmacocinética , Aztreonam/farmacocinética , Microdiálise/métodos , Peritonite/tratamento farmacológico , Animais , Líquido Ascítico/metabolismo , Compostos Azabicíclicos/uso terapêutico , Aztreonam/uso terapêutico , Masculino , Músculo Esquelético/metabolismo , Peritonite/metabolismo , Ratos , Ratos Sprague-Dawley
7.
Basic Clin Pharmacol Toxicol ; 123(4): 407-422, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29665289

RESUMO

Colistin is a polymyxin antibiotic used to treat patients infected with multidrug-resistant Gram-negative bacteria (MDR-GNB). The objective of this work was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model to predict tissue distribution of colistin in rat. The distribution of a drug in a tissue is commonly characterized by its tissue-to-plasma partition coefficient, Kp . Colistin and its prodrug, colistin methanesulfonate (CMS) Kp priors, were measured experimentally from rat tissue homogenates or predicted in silico. The PK parameters of both compounds were estimated fitting in vivo their plasma concentration-time profiles from six rats receiving an i.v. bolus of CMS. The variability in the data was quantified by applying a nonlinear mixed effect (NLME) modelling approach. A WB-PBPK model was developed assuming a well-stirred and perfusion-limited distribution in tissue compartments. Prior information on tissue distribution of colistin and CMS was investigated following three scenarios: Kp was estimated using in silico Kp priors (I) or Kp was estimated using experimental Kp priors (II) or Kp was fixed to the experimental values (III). The WB-PBPK model best described colistin and CMS plasma concentration-time profiles in scenario II. Colistin-predicted concentrations in kidneys in scenario II were higher than in other tissues, which was consistent with its large experimental Kp prior. This might be explained by a high affinity of colistin for renal parenchyma and active reabsorption into the proximal tubular cells. In contrast, renal accumulation of colistin was not predicted in scenario I. Colistin and CMS clearance estimates were in agreement with published values. The developed model suggests using experimental priors over in silico Kp priors for kidneys to provide a better prediction of colistin renal distribution. Such models might serve in drug development for interspecies scaling and investigate the impact of disease state on colistin disposition.


Assuntos
Antibacterianos/farmacocinética , Colistina/análogos & derivados , Modelos Biológicos , Pró-Fármacos/farmacocinética , Ativação Metabólica , Animais , Antibacterianos/administração & dosagem , Colistina/administração & dosagem , Colistina/farmacocinética , Simulação por Computador , Injeções Intravenosas , Masculino , Pró-Fármacos/administração & dosagem , Ratos Sprague-Dawley , Distribuição Tecidual
8.
J Control Release ; 271: 118-126, 2018 02 10.
Artigo em Inglês | MEDLINE | ID: mdl-29277683

RESUMO

Ciprofloxacin (CIP) apparent permeability across a pulmonary epithelium model can be controlled by the affinity of its complex with a metal cation. The higher the complex affinity, the larger is the reduction in CIP apparent permeability. The aim of this study was to evaluate if the control of the CIP apparent permeability observed in vitro could be transposed in vivo to control the CIP lung-to-blood absorption rate and CIP concentrations in the lung epithelial lining fluid (ELF) after intratracheal (IT) administration. Two types of innovative inhalable microparticles loaded with the low-affinity CIP-calcium complex (CIP-Ca) or with the high-affinity CIP-copper complex (CIP-Cu) were formulated and characterized. Then, ELF and plasma pharmacokinetics of CIP were studied in rats after IT administration of these two types of microparticles and of a CIP solution (2.5mg/kg). The presence of Cu2+ had little effect on the microparticle properties and the dry powder had aerodynamic properties which allowed it to reach the lungs. CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively. No significant modification of lung toxicity markers was found (lactate dehydrogenase and total protein). CIP complexation with Cu2+ seems to be an interesting approach to obtain high CIP concentrations in the ELF of lungs after dry powder IT administration.


Assuntos
Antibacterianos/administração & dosagem , Cálcio/administração & dosagem , Ciprofloxacina/administração & dosagem , Cobre/administração & dosagem , Pulmão/metabolismo , Administração por Inalação , Aerossóis , Animais , Antibacterianos/farmacocinética , Cálcio/farmacocinética , Ciprofloxacina/farmacocinética , Cobre/farmacocinética , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/farmacocinética , Masculino , Pós , Ratos Sprague-Dawley
9.
Eur J Pharm Sci ; 93: 184-91, 2016 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-27531420

RESUMO

A comparative pharmacokinetic study was conducted in rats after intratracheal aerosolization of levofloxacin, as a solution, as immediate-release chitosan microspheres or as sustained-release PLGA microspheres. A pharmacokinetic model was constructed to model levofloxacin concentrations both in plasma and in the lung epithelial lining fluid (ELF). The plasma and ELF experimental concentration profiles versus time were similar for the intravenous and intratracheal levofloxacin solutions and for the intratracheal levofloxacin-loaded chitosan microsphere dry powder, indicating that levofloxacin diffused almost instantaneously through the broncho-alveolar barrier and that the chitosan microspheres released levofloxacin very rapidly, as anticipated from in vitro release studies. The bioavailability for the intratracheal levofloxacin solution and intratracheal chitosan microspheres was estimated to be 98% and 71%, respectively, both with a direct release into the ELF compartment. The ELF-to-unbound plasma AUC ratios were slightly above 2 and may result from an efflux transport. For the intratracheal PLGA microspheres, a high ELF-to-unbound plasma AUC concentration ratio (311) was observed and high levofloxacin concentrations were maintained in ELF for at least 72h in consistency with the in vitro release studies. The bioavailability was 92%, with 19% of the dose released immediately (burst release) into the ELF and 73% released slowly into the ELF from a depot compartment, i.e. the PLGA microspheres, according to a Weibull model. These results highlight the benefit of using sustained-release microspheres administered as aerosols to provide and to maintain high pulmonary concentrations of an antibiotic characterized with a high permeability profile through the broncho-alveolar barrier. The sustained-release microsphere dry powder aerosol may therefore provide advantages over solutions or pure drug dry powders for inhalation in terms of treatment efficiency, ease of use and frequency of administration.


Assuntos
Antibacterianos , Quitosana/química , Ácido Láctico/química , Levofloxacino , Ácido Poliglicólico/química , Administração por Inalação , Aerossóis , Animais , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Antibacterianos/química , Antibacterianos/farmacocinética , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/química , Preparações de Ação Retardada/farmacocinética , Levofloxacino/administração & dosagem , Levofloxacino/sangue , Levofloxacino/química , Levofloxacino/farmacocinética , Masculino , Microesferas , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Ratos Sprague-Dawley
10.
Antimicrob Agents Chemother ; 60(8): 5085-7, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27297482

RESUMO

The aim of this study was to determine the biopharmaceutical characteristics of oseltamivir carboxylate (OC) after pulmonary delivery. After OC bolus and intratracheal nebulization (NEB) in rats, blood was collected and bronchoalveolar lavages (BALs) were performed. Epithelial lining fluid (ELF) concentrations were estimated from BAL fluid. The area under the curve (AUC) ratio for ELF to plasma was 842 times higher after NEB than after intravenous (i.v.) administration, indicating that OC nebulization offers a biopharmaceutical advantage over i.v. administration.


Assuntos
Anti-Infecciosos/sangue , Oseltamivir/análogos & derivados , Administração por Inalação , Administração Intravenosa , Animais , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Antibacterianos/farmacocinética , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/farmacocinética , Área Sob a Curva , Lavagem Broncoalveolar , Masculino , Oseltamivir/administração & dosagem , Oseltamivir/sangue , Oseltamivir/farmacocinética , Ratos , Ratos Sprague-Dawley
11.
Brain ; 139(Pt 6): 1762-82, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-27084575

RESUMO

The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth during development, and after central nervous system injury. We have discovered a novel piperazine-derived compound, EVT901, which interferes with p75 neurotrophin receptor oligomerization through direct interaction with the first cysteine-rich domain of the extracellular region. Using ligand binding assays with cysteine-rich domains-fused p75 neurotrophin receptor, we confirmed that EVT901 interferes with oligomerization of full-length p75 neurotrophin receptor in a dose-dependent manner. Here we report that EVT901 reduces binding of pro-nerve growth factor to p75 neurotrophin receptor, blocks pro-nerve growth factor induced apoptosis in cells expressing p75 neurotrophin receptor, and enhances neurite outgrowth in vitro Furthermore, we demonstrate that EVT901 abrogates p75 neurotrophin receptor signalling by other ligands, such as prion peptide and amyloid-ß. To test the efficacy of EVT901 in vivo, we evaluated the outcome in two models of traumatic brain injury. We generated controlled cortical impacts in adult rats. Using unbiased stereological analysis, we found that EVT901 delivered intravenously daily for 1 week after injury, reduced lesion size, protected cortical neurons and oligodendrocytes, and had a positive effect on neurological function. After lateral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the hippocampus and thalamus, reduced long-term cognitive deficits, and reduced the occurrence of post-traumatic seizure activity. Together, these studies provide a new reagent for altering p75 neurotrophin receptor actions after injury and suggest that EVT901 may be useful in treatment of central nervous system trauma and other neurological disorders where p75 neurotrophin receptor signalling is affected.


Assuntos
Oligodendroglia/efeitos dos fármacos , Piperazinas/farmacologia , Receptor de Fator de Crescimento Neural/antagonistas & inibidores , Animais , Apoptose/efeitos dos fármacos , Lesões Encefálicas Traumáticas/metabolismo , Lesões Encefálicas Traumáticas/patologia , Contagem de Células , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Doenças Desmielinizantes/patologia , Relação Dose-Resposta a Droga , Humanos , Masculino , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Oligodendroglia/metabolismo , Fosforilação/efeitos dos fármacos , Cultura Primária de Células , Ensaio Radioligante , Ratos , Receptor de Fator de Crescimento Neural/biossíntese , Receptor trkA/metabolismo , Recuperação de Função Fisiológica
12.
Antimicrob Agents Chemother ; 60(5): 3196-8, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-26926626

RESUMO

The aim of this study was to determine aztreonam (ATM) membrane permeability using Calu-3 cells and its plasma and pulmonary epithelial lining fluid (ELF) pharmacokinetics in rats after intratracheal nebulization and intravenous administration (15 mg · kg(-1)). ATM exhibits low Calu-3 permeability (0.07 ± 0.02 × 10(-6) cm · s(-1)), and a high area under the ELF/unbound plasma concentration time curve between 0 and infinity (AUCELF/AUCu,plasma) ratio of 1,069 was observed after nebulization in rats. These results confirm that ATM is a low-permeability molecule and a good candidate for nebulization.


Assuntos
Antibacterianos/farmacologia , Anti-Infecciosos/farmacologia , Aztreonam/farmacologia , Administração por Inalação , Animais , Antibacterianos/administração & dosagem , Anti-Infecciosos/administração & dosagem , Aztreonam/administração & dosagem , Pulmão/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley
13.
Antimicrob Agents Chemother ; 59(10): 6646-7, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26239992

RESUMO

The aim of this study was to determine the biopharmaceutical characteristics of tobramycin (TOB) after nebulization in rats. TOB was administered by intravenous (i.v.) bolus or intratracheal nebulization (3 mg · kg(-1)), and concentrations were determined in plasma and epithelial lining fluid (ELF) by liquid chromatography-tandem mass spectrometry. The ratio of the TOB concentration in ELF to the plasma area under the curve (AUC) was more than 200 times as high after NEB as after i.v. bolus administration, indicating that TOB nebulization offers a biopharmaceutical advantage over i.v. administration.


Assuntos
Anti-Infecciosos/farmacocinética , Tobramicina/farmacocinética , Animais , Antibacterianos , Anti-Infecciosos/administração & dosagem , Cromatografia Líquida , Masculino , Nebulizadores e Vaporizadores , Ratos , Ratos Sprague-Dawley , Espectrometria de Massas em Tandem , Tobramicina/administração & dosagem
14.
Antimicrob Agents Chemother ; 58(7): 3942-9, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24798283

RESUMO

The aim of this study was to evaluate the biopharmaceutical characteristics of three fluoroquinolones (FQs), ciprofloxacin (CIP), moxifloxacin (MXF), and grepafloxacin (GRX), after delivery via a nebulized aerosol to rats. Bronchoalveolar lavages (BAL) were conducted 0.5, 2, 4, and 6 h after FQ intravenous administration and nebulized aerosol delivery to estimate epithelial lining fluid (ELF) drug concentrations. Plasma drug concentrations were also measured, and profiles of drug concentrations versus time after intravenous administration and nebulized aerosol delivery were virtually superimposable, attesting for rapid and complete systemic absorption of FQs. ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations). The impact of macrophage lysis on estimated ELF drug concentrations was significant for GRX but reduced for MXF and CIP; therefore, simultaneous pharmacokinetic modeling of plasma and ELF drug concentrations was only performed for the latter two drugs. The model was characterized by a fixed volume of ELF (VELF), passive diffusion clearance (QELF), and active efflux clearance (CLout) between plasma and ELF, indicating active efflux transport systems. In conclusion, this study demonstrates that ELF drug concentrations of these three FQs are several times higher than plasma drug concentrations, probably due to the presence of efflux transporters at the pulmonary barrier level, but no biopharmaceutical advantage of FQ nebulization was observed compared with intravenous administration.


Assuntos
Antibacterianos/farmacocinética , Ciprofloxacina/farmacocinética , Fluoroquinolonas/farmacocinética , Piperazinas/farmacocinética , Administração por Inalação , Aerossóis , Animais , Antibacterianos/administração & dosagem , Biofarmácia , Líquido da Lavagem Broncoalveolar/química , Linhagem Celular , Ciprofloxacina/administração & dosagem , Fluoroquinolonas/administração & dosagem , Humanos , Macrófagos Alveolares/metabolismo , Masculino , Moxifloxacina , Piperazinas/administração & dosagem , Ratos , Ratos Sprague-Dawley , Ureia/análise
15.
Antimicrob Agents Chemother ; 58(7): 3950-6, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24798284

RESUMO

The purpose of this study was to investigate the pharmacokinetic properties of colistin following intrapulmonary administration of colistin sulfate in rats. Colistin was infused or delivered in nebulized form at a dose of 0.35 mg/kg of body weight in rats, and plasma drug concentrations were measured for 4 h after administration. Bronchoalveolar lavages (BAL) were also conducted at 0.5, 2, and 4 h after intravenous (i.v.) administration and administration via nebulized drug to estimate epithelial lining fluid (ELF) drug concentrations. Unbound colistin plasma concentrations at distribution equilibrium (2 h postdosing) were almost identical after i.v. infusion and nebulized drug inhalation. ELF drug concentrations were undetectable in BAL samples after i.v. administration, but they were about 1,800 times higher than unbound plasma drug levels at 2 h and 4 h after administration of the nebulized drug. Simultaneous pharmacokinetic modeling of plasma and ELF drug concentrations was performed with a model characterized by a fixed physiological volume of ELF (VELF), a passive diffusion clearance (QELF) between plasma and ELF, and a nonlinear influx transfer from ELF to the central compartment, which was assessed by reducing the nebulized dose of colistin by 10-fold (0.035 mg kg(-1)). The km was estimated to be 133 µg ml(-1), and the Vmax, in-to-Km ratio was equal to 2.5 × 10(-3) liter h(-1) kg(-1), which was 37 times higher than the QELF (6.7 × 10(-5) liter h(-1) kg(-1)). This study showed that with the higher ELF drug concentrations after administration via nebulized aerosol than after intravenous administration, for antibiotics with low permeability such as colistin, nebulization offers a real potential over intravenous administration for the treatment of pulmonary infections.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Colistina/administração & dosagem , Colistina/farmacologia , Administração por Inalação , Administração Intravenosa , Aerossóis , Algoritmos , Animais , Antibacterianos/farmacocinética , Área Sob a Curva , Biofarmácia , Líquido da Lavagem Broncoalveolar/química , Colistina/farmacocinética , Masculino , Ratos , Ratos Sprague-Dawley
16.
Eur J Pharm Biopharm ; 86(2): 133-44, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24333401

RESUMO

This work aimed at designing a formulation based on nanostructured lipid carriers (NLC) for transdermal co-administration of olanzapine and simvastatin, using passive and active strategies in a combined in vitro/in vivo development approach. NLC were prepared by two distinct methods, namely solvent emulsification-evaporation (SE/E) and high pressure homogenization (HPH). HPH was selected on the basis of a better performance in terms of drug loading and in vitro permeation rate. Several mathematical models were used to elucidate the release mechanisms from lipid nanoparticles. In vitro release kinetics was shown to be driven by diffusion, but other mechanisms were also present, and supported the feasibility of using NLC for sustained drug delivery. The in vitro skin studies showed that the chemical penetration enhancers, limonene and ethanol, added to the NLC formulations, promoted a synergistic permeation enhancement of both drugs, with olanzapine exhibiting a higher permeation than simvastatin. Transdermal administration to rats resulted in steady-state levels reached at around 10h and maintained for 48h, again with olanzapine exhibiting a better permeation rate. The pharmacokinetic parameters indicated that the NLC dispersion displayed a better in vivo performance than the gel, which was consistent with the in vitro results. These differences were, however, negligible in the flux values, supporting the use of gel as a final, more convenient, formulation. The in vivo experiments in rats correlated well with in vitro findings and revealed that the combined use of ethanol and limonene, incorporated in the NLC formulation, provided the main driving force for drug permeation. The Dermaroller® pretreatment did not significantly enhance drug permeation, supporting the use of passive methods as suitable for a transdermal delivery system. Furthermore, this work may provide a promising proof-of-concept for further clinical application in the treatment of schizophrenia and associated disorders, combined with dyslipidemia.


Assuntos
Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/química , Lipídeos/administração & dosagem , Lipídeos/química , Nanoestruturas/administração & dosagem , Nanoestruturas/química , Pele/metabolismo , Administração Cutânea , Animais , Benzodiazepinas/administração & dosagem , Benzodiazepinas/química , Benzodiazepinas/metabolismo , Química Farmacêutica/métodos , Cicloexenos/administração & dosagem , Cicloexenos/química , Cicloexenos/metabolismo , Portadores de Fármacos/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Géis/administração & dosagem , Géis/química , Géis/metabolismo , Humanos , Limoneno , Masculino , Olanzapina , Tamanho da Partícula , Permeabilidade , Ratos , Ratos Sprague-Dawley , Sinvastatina/administração & dosagem , Sinvastatina/química , Sinvastatina/metabolismo , Absorção Cutânea , Suínos , Terpenos/administração & dosagem , Terpenos/química , Terpenos/metabolismo
17.
Eur J Pharm Sci ; 51: 45-50, 2014 Jan 23.
Artigo em Inglês | MEDLINE | ID: mdl-23999032

RESUMO

Hypovolemia is a common event in critical care patients that may affect drug distribution and elimination. In order to better understand this issue the effect of hypovolemia on the plasma protein binding and tissue distribution of ertapenem was investigated in rats using microdialysis. Microdialysis probes were inserted into the jugular vein and hind leg muscle. Ertapenem recoveries in muscle and blood were determined in each rat by retrodialysis by drug before drug administration. Hypovolemia was induced in 6 rats by removing 40% of the initial blood volume over 30 min. Ertapenem was infused intravenously at a dose of 40 mg kg(-1) over 30 min, and microdialysis samples were collected for 310 min. The unbound concentration profiles in muscle and blood were virtually superimposed in both groups except at early time points. The ratios of the area under the concentration-time curve (AUC) for tissue to the AUC for blood were 0.7±0.2 and 0.8±0.2 for control and hypovolemic rats, respectively. Hypovolemia induced a 40% decrease in the clearance of ertapenem, with no statistically significant alteration of its volume of distribution. This study showed that ertapenem elimination was altered in hypovolemic rats, probably due to decreased renal blood flow, but its distribution characteristics were not. Unbound concentrations of ertapenem in blood and muscle were always virtually identical.


Assuntos
Hipovolemia/fisiopatologia , Distribuição Tecidual/fisiologia , beta-Lactamas/metabolismo , Animais , Área Sob a Curva , Ertapenem , Masculino , Microdiálise/métodos , Músculo Esquelético/metabolismo , Músculo Esquelético/fisiopatologia , Ratos , Ratos Sprague-Dawley , Circulação Renal/fisiologia
18.
Antimicrob Agents Chemother ; 56(7): 3531-4, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22526310

RESUMO

The aim of this study was to determine the penetration of doripenem administered intravenously into the rabbit aqueous and vitreous humors. Nineteen New Zealand White rabbits received a 20-mg dose of doripenem intravenously over 60 min. Specimens of aqueous humor, vitreous humor, and blood were obtained 30 min (n = 5), 1 h (n = 5), 2 h (n = 5), and 3 h (n = 4) after the beginning of the infusion and analyzed by high-performance liquid chromatography (HPLC). A pharmacokinetic (PK) model was developed to fit the experimental data. Doripenem concentrations in aqueous humor were lower than those in plasma ultrafiltrates at all sampling times, with an average aqueous humor-to-plasma ultrafiltrate area under the concentration-time curve ratio estimated as 8.3%. A pharmacokinetic model with peripheral elimination described the data adequately and was tentatively used to predict concentration-versus-time profiles and pharmacokinetic-pharmacodynamic (PK-PD) target attainment in patients under various dosing regimens. In conclusion, systematically administered doripenem does not seem to be a promising approach for the treatment of intraocular infections, especially since it could not be detected in the vitreous humor. However, this study has provided an opportunity to develop a new PK modeling approach to characterize the intraocular distribution of doripenem administered intravenously to rabbits, with tentative extrapolation to humans.


Assuntos
Carbapenêmicos/administração & dosagem , Carbapenêmicos/farmacocinética , Infusões Intravenosas/métodos , Animais , Humor Aquoso/metabolismo , Carbapenêmicos/sangue , Doripenem , Humanos , Coelhos , Corpo Vítreo/metabolismo
19.
J Antimicrob Chemother ; 65(8): 1753-8, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20507861

RESUMO

OBJECTIVES: The aim of this study was to evaluate the effect of colistin methanesulphonate (CMS) dose on CMS and colistin pharmacokinetics in rats. METHODS: Three rats per group received an intravenous bolus of CMS at a dose of 5, 15, 30, 60 or 120 mg/kg. Arterial blood samples were drawn at 0, 5, 15, 30, 60, 90, 120, 150 and 180 min. CMS and colistin plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters of CMS and colistin were calculated by non-compartmental analysis. RESULTS: Linear relationships were observed between CMS and colistin AUCs to infinity and CMS doses, as well as between CMS and colistin C(max) and CMS doses. CONCLUSIONS: CMS and colistin pharmacokinetics were linear for a range of colistin concentrations covering the range of values encountered and recommended in patients even during treatment with higher doses.


Assuntos
Antibacterianos/farmacocinética , Colistina/análogos & derivados , Colistina/farmacocinética , Animais , Antibacterianos/administração & dosagem , Cromatografia Líquida , Colistina/administração & dosagem , Injeções Intravenosas , Masculino , Plasma/química , Ratos , Ratos Sprague-Dawley , Espectrometria de Massas em Tandem
20.
Antimicrob Agents Chemother ; 52(4): 1516-8, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18195055

RESUMO

Imipenem distribution was characterized by microdialysis in the peritoneal fluid of rats with experimental pancreatitis. The ratios of peritoneal fluid to blood area under unbound concentration-versus-time curves were close to unity, suggesting that imipenem was not degraded in peritoneal fluid.


Assuntos
Antibacterianos/farmacocinética , Líquido Ascítico/metabolismo , Imipenem/farmacocinética , Microdiálise , Pancreatite/tratamento farmacológico , Doença Aguda , Animais , Antibacterianos/administração & dosagem , Área Sob a Curva , Líquido Ascítico/química , Imipenem/administração & dosagem , Injeções Intravenosas , Masculino , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...